Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 15/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12577159 | 0.89 | HSD11B1 (0.80) | HSD11B1SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL19172961 | 0.88 | HSD11B1 (1.00) | HSD11B1SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL19173949 | 0.85 | HSD11B1 (0.74) | HSD11B1SMN1; SMN2ALDH1A1 | |
| SCHEMBL19173935 | 0.84 | HSD11B1 (1.00) | HSD11B1SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL3455384 | 0.82 | SMN1; SMN2 (1.00) | HSD11B1SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL19173468 | 0.77 | ALDH1A1 (0.98) | HSD11B1SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL29340189 | 0.76 | HSD11B1 (0.62) | HSD11B1SMN1; SMN2 | |
| SCHEMBL19150618 | 0.76 | HSD11B1 (0.86) | HSD11B1SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL4203726 | 0.75 | HSD11B1 (0.60) | HSD11B1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL417886 | 0.74 | MEN1 (0.72) | HSD11B1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12240857-B2 | Adamantane derivatives for the treatment of filovirus infection | ARISAN THERAPEUTICS INC. (US) | 2025-03-04 | — | — | US | disclosed |
| US-20240238265-A1 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240238265-A1 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2024-07-18 | — | — | US | disclosed |
| WO-2021262426-A2 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| WO-2017127306-A1 | ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTION | ARISAN THERAPEUTICS (US) | 2017-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12240857-B2 | Adamantane derivatives for the treatment of filovirus infection | IFNAR1, MEP1B, MEP1A | HSD11B1 1438/4885SMN1; SMN2 521/4885ALDH1A1 652/4885 |
| US-20240238265-A1 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | IFNAR1, NR4A3, NR0B2 | HSD11B1 2165/4885SMN1; SMN2 1174/4885ALDH1A1 2758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.